FDA Cleared Wellysis CardioAI Software

The regulatory approval allows the company to bring its automated ECG analysis tool to the U.S. market.

Updated on Oct. 9, 2026 in Healthcare

Live Poll

Do you trust AI-powered software to help doctors interpret your heart health data accurately?

The FDA has granted 510(k) clearance to the S-Patch CardioAI, a Class II medical device software. Developed by Wellysis, the technology is designed to automate ECG analysis to assist with professional clinical interpretation.

Why it matters

Healthcare organizations face increasing pressure to manage high volumes of cardiac data efficiently. This software provides a streamlined solution that integrates into existing clinical workflows to support faster, more accurate patient reviews.

Wellysis reported that its U.S. revenue quadrupled between 2024 and 2025. The company currently operates its U.S. subsidiary out of the Texas Medical Center in Houston.

The players

Wellysis

Wellysis is a health technology firm and spin-off of Samsung SDS that specializes in cardiac monitoring solutions.

Samsung SDS

Samsung SDS is a global information technology service provider and the parent company from which Wellysis emerged.

FDA

The Food and Drug Administration is the federal agency responsible for regulating medical devices in the United States.

The details

The S-Patch CardioAI software automates ECG analysis to support professional interpretation and integrates into third-party ECG platforms. Wellysis plans to deploy the technology to its existing U.S. customer base using both subscription and per-test commercial models.

Wellysis spun off from Samsung SDS in 2019.
The company established its Houston subsidiary in 2023.
U.S. revenue for Wellysis more than quadrupled between 2024 and 2025.
The FDA granted 510(k) clearance to CardioAI on September 25, 2026.

Market Landscape

The approval of CardioAI reflects the ongoing digitalization of cardiac diagnostics as firms race to integrate AI into clinical infrastructure. This positions Wellysis to compete more aggressively against established diagnostic providers by offering automated workflow efficiencies.

Patients may experience faster turnaround times for cardiac test results as clinical staff adopt these automated analysis tools. Healthcare providers can expect new integration options for existing diagnostic platforms through Wellysis subscription and per-test models.

The takeaway

Artificial intelligence is becoming a core component of routine medical diagnostic workflows to manage rising caseloads. Healthcare providers looking to optimize efficiency should evaluate how automated ECG analysis tools can reduce the administrative burden on cardiologists.